Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Clinical Laserthermia Systems AB's EV-to-OCF or its related term are showing as below:
FRA:LS60'
s EV-to-OCF Range Over the Past 10 Years
Min: -30.59 Med: -3.87 Max: -0.26
Current: -1.31
During the past 13 years, the highest EV-to-OCF of Clinical Laserthermia Systems AB was -0.26. The lowest was -30.59. And the median was -3.87.
FRA:LS60's EV-to-OCF is ranked better than 64.71% of 853
companies
in the Medical Devices & Instruments industry
Industry Median: 7.94
vs FRA:LS60: -1.31
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Clinical Laserthermia Systems AB (FRA:LS60) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Clinical Laserthermia Systems AB's PE Ratio (TTM) for today is calculated as:
Clinical Laserthermia Systems AB's share price for today is €0.121.
Clinical Laserthermia Systems AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.117.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Clinical Laserthermia Systems AB EV-to-OCF Related Terms
Clinical Laserthermia Systems AB EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Clinical Laserthermia Systems AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clinical Laserthermia Systems AB EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Clinical Laserthermia Systems AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Clinical Laserthermia Systems AB's EV-to-OCF falls into.
Clinical Laserthermia Systems AB's current Enterprise Value is €3.10 Mil.
Clinical Laserthermia Systems AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Clinical Laserthermia Systems AB (FRA:LS60) has a EV-to-OCF of -1.35 as of Aug. 14, 2026. According to the industry distribution chart, Clinical Laserthermia Systems AB ranks #301 out of 853 companies in the Medical Devices & Instruments industry, placing it in the top 35.3%.
Is Clinical Laserthermia Systems AB's EV-to-OCF too high?
Clinical Laserthermia Systems AB's current EV-to-OCF is -1.35. Based on the distribution chart, Clinical Laserthermia Systems AB ranks #301 out of 853 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Clinical Laserthermia Systems AB has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Clinical Laserthermia Systems AB's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Clinical Laserthermia Systems AB ranks #301 out of 853 companies for EV-to-OCF. This puts Clinical Laserthermia Systems AB in the upper half of its industry. The industry median EV-to-OCF is 7.94. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.94, based on 853 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Clinical Laserthermia Systems AB's current EV-to-OCF is -1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clinical Laserthermia Systems AB stock overvalued right now?
Based on GuruFocus' analysis, Clinical Laserthermia Systems AB (FRA:LS60) is currently considered Possible Value Trap. The stock's GF Value™ is €0.21, compared to a current price of €0.12 — trading 42.4% below its estimated fair value. The current EV-to-OCF is -1.35. Clinical Laserthermia Systems AB's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Clinical Laserthermia Systems AB (FRA:LS60), the current EV-to-OCF is -1.35 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Clinical Laserthermia Systems AB (FRA:LS60) Overvalued in 2026?
Based on GuruFocus' analysis, Clinical Laserthermia Systems AB stock appears to be undervalued.
The current stock price of €0.12 is trading 42.4% below its estimated GF Value™ of €0.21.
GuruFocus considers Clinical Laserthermia Systems AB to be Possible Value Trap.
Key valuation signals for FRA:LS60:
EV-to-OCF: -1.35
GF Value™: €0.21 vs. price of €0.12 (42.4% below fair value)
No single metric tells the full story. See the FRA:LS60 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Clinical Laserthermia Systems AB develops and sells single-use products used during each treatment procedure of treatment of solid tumors cancers. Its products include Thermal Therapy System, Mobile Laser Unit, Laser Applicator Non-cooled and Tissue Temp Probe.
41GF Score
Get the complete analysis for FRA:LS60
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LS60 has been successfully added to your 
